Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer in first human trial
NCT ID NCT06492122
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new radioactive drug called FL-020 in 50 men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The drug is designed to seek out and deliver radiation directly to cancer cells. The main goals are to check safety, find the right dose, and see early signs of whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A radioactive drug called FL-020 (attached to actinium-225) given by IV
What this could lead to
If it works, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a very early, small phase 1 trial with only 50 participants, so safety and dosing are still being figured out. The radioactive drug may cause side effects, and there is no guarantee it will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ankara Üniversitesi Tıp Fakültesi Cebeci Hastanesi Nükleer Tıp Anabilim Dalı
RECRUITINGAnkara, 06590, Turkey (Türkiye)
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Cancer Hospital
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Chao Family Comprehensive Cancer Center
RECRUITINGIrvine, California, 92612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact
-
Genesiscare Murdoch
RECRUITINGMurdoch, Australia
Contact
Contact
-
MacQuarie University Clinical Trial Unit
RECRUITINGSydney, NSW 2109, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Princess Alexandra Hospital
RECRUITINGBrisbane, Australia
Contact
Contact
-
Renji Shanghai Hospital
RECRUITINGShanghai, 200002, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospital of Cleveland
RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Stanford
RECRUITINGStanford, California, 94305, United States
Contact
Contact
Contact
-
University of Virginia Cancer Center
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••